FDA Grants Orphan Drug Designation to Neuralstem's Treatment for Angelman Syndrome

FDA Grants Orphan Drug Designation to Neuralstem's Treatment for Angelman Syndrome

Submitted by admin on August 9, 2018 - 3:55pm
Source: 
CP Wire
News Tags: 
Neuralstem
Angelman Syndrome
NSI-189
Headline: 
FDA Grants Orphan Drug Designation to Neuralstem's Treatment for Angelman Syndrome
snippet: 

Neuralstem, Inc. (Nasdaq:CUR) announced on 8/9/18 that the U.S. Food and Drug Administration has granted orphan drug designation to NSI-189 for the treatment of Angelman syndrome.

Do Not Allow Advertisers to Use My Personal information